Wells Fargo & Company Gain Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 2,650 shares of GANX stock, worth $6,598. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,650
Previous 2,650
-0.0%
Holding current value
$6,598
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding GANX
# of Institutions
24Shares Held
2.52MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.47 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.41 Million0.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$833,1340.01% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$665,8780.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$440,9160.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $29.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...